Processa Pharmaceuticals, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Processa Pharmaceuticals, a clinical-stage biopharmaceutical company, is conducting a public offering of common stock and warrants to raise up to $7.0 million, aiming to fund its Phase 2 clinical trial for NGC-Cap and address its significant accumulated deficit and going concern issues.
NASDAQ
Processa Pharmaceuticals is seeking to raise capital through a public offering of common stock, pre-funded warrants, and common stock purchase warrants.
NASDAQ
Processa Pharmaceuticals has filed an amendment to its registration statement for a public offering of up to 9,400,705 shares of common stock, pre-funded warrants, and common warrants.
NASDAQ
S-1: Processa Pharmaceuticals Seeks Up to $7.5 Million in Public Offering to Advance Cancer Drug Pipeline
Processa Pharmaceuticals is launching a public offering of common stock and pre-funded warrants to raise capital for its NGC-Cap Phase 2 clinical trial and general corporate purposes.
NASDAQ
Processa Pharmaceuticals is launching a public offering to raise capital for a Phase 2 clinical trial of its NGC-Cap drug and for general corporate purposes.